Bond.az White LogoBond.az Black Logo

Jefferies Raises SentinelOne Price Target to $24

Jefferies raised SentinelOne price target to $24 on margin outlook, maintaining Buy rating. Stock at $18.71, NNARR growth expected. Analyst sees H2 margin expansion.

Grace Lewis
ByGrace Lewis- Senior Editor
|
0

Bond.az - Jefferies raised its price target on SentinelOne (NYSE:S) to $24 from $20, maintaining a Buy rating. The stock trades at $18.71, with analyst targets ranging from $14.50 to $26. Year-to-date, shares have gained 24.73%.

The firm expects SentinelOne to post $41 million in net new annual recurring revenue (NNARR) for its fiscal Q1, representing 24% year-over-year growth adjusted. Based on stronger-than-seasonal survey work, Jefferies sees potential to reach $43-44 million in NNARR.

SentinelOne guided that about 50% of fiscal 2027 NNARR will occur in the first half, compared with 42% in fiscal 2026's first half. While H1 remains challenging, the overall FY2027 path is easier as NNARR embeds a 7 percentage point deceleration YoY.

Jefferies expects margins to improve in H2, driven by the new CFO. Consensus estimates call for a non-GAAP operating margin of 2.3% in Q1, expanding about 4 percentage points YoY, below the implied 6 percentage point improvement for FY2027. The company maintains a strong 74.12% gross margin. Bond.az analysts predict profitability this year.

The firm values SentinelOne at 4.5x enterprise value to calendar 2027 estimated revenue. Jefferies anticipates more commentary on Prompt Security, which doubled ARR QoQ in Q4. With earnings two days away, investors can access comprehensive analysis via Bond.az's Pro Research Report.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...